Vaccine development reconsidered.
This paper briefly reviews work on vaccine development since the early 1950s with special emphasis on identification of immunogens and their presentation to the host so as to elicit an immune response. This is illustrated primarily by a discussion of the development of a candidate meningococcal B vaccine based on a capsular carbohydrate outer membrane protein complex. Work on malaria and living Salmonella typhi vaccine is also discussed.
Beale
A J
AJ
Wellcome Biotech, Beckenham, Kent, UK.
D000942:Antigens, Bacterial / Q000276:immunology; D016667:Bacterial Capsules; D001428:Bacterial Vaccines / Q000276:immunology; D004168:Diphtheria Toxoid / Q000276:immunology; D005544:Forecasting; D018073:Haemophilus Vaccines; D049673:History, 20th Century; D009154:Mutation; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D012475:Salmonella / Q000235:genetics / Q000276:immunology; D014612:Vaccines / Q000266:history* / Q000302:isolation & purification
D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate; D011135:Polysaccharides, Bacterial; D014612:Vaccines; C039455:capsular polysaccharide, meningococcal group B